Activation of Human T Lymphocytes: Differential Effects of CD3- and CD8-Mediated Signals

Total Page:16

File Type:pdf, Size:1020Kb

Activation of Human T Lymphocytes: Differential Effects of CD3- and CD8-Mediated Signals Proc. Natl. Acad. Sci. USA Vol. 85, pp. 9689-9693, December 1988 Immunology Activation of human T lymphocytes: Differential effects of CD3- and CD8-mediated signals (protein phosphorylation/CD3 modulation/interleukin 2 receptor/interleukin 2/interferon 'y) YVONNE SAMSTAG*, FRANK EMMRICHt, AND THEOPHIL STAEHELINt Max-Planck-Institut fur Immunbiologie, 7800 Freiburg, Federal Republic of Germany Communicated by Niels K. Jerne, July 18, 1988 (received for review March 9, 1988) ABSTRACT T cells are activated physiologically by trig- Ca2", activation of protein kinase C (PKC), phosphorylation gering the T-cell receptor-CD3 complex. There is evidence that of components of the CD3 complex, and endocytosis (mod- invariant accessory molecules on the T-cell membrane (CD8 ulation) of TCR-CD3 (for review, see refs. 10-15 and 16). and CD4) are involved in the major histocompatibility com- However, neither the correct sequence of these events nor plex-restricted recognition process. Moreover, binding and their absolute necessity are known for effects related to T-cell crosslinking ofthese accessory molecules to the T-cell receptor- function, such as expression of growth factor receptors and CD3 complex exerts a positive synergistic signal, as has been lymphokine secretion. shown by stimulation with crosslinked antibodies. Here we Here we characterize and compare the polyclonal stimu- demonstrate that stimulation mediated by immobilized lation of purified resting T cells by immobilized anti-CD3 anti-CD3/CD8 antibodies differs from stimulation mediated versus stimulation by immobilized anti-CD3 plus anti-CD8 solely by anti-CD3. Whereas interleukin 2 receptor expression monoclonal antibodies (mAbs) with respect to TCR-CD3 and interferon y production are seen to a similar extent in both modulation and CD3 phosphorylation as well as the induction cases, a second signal provided by the additional involvement of specific functions [interleukin 2 (IL-2) receptor (IL-2R) of CD8 seems to be essential for interleukin 2 production and expression and IL-2 and interferon y (IFN-y) secretion]. full interleukin 2 responsiveness in CD8' T cells. This second Further, we asked whether the effects of the CD3- or signal is much more sensitive to inhibition by 1-(5- CD8-mediated stimuli depend selectively on specific protein isoquinolinylsulfonyl)-2-methylpiperazine, an inhibitor of pro- kinases, including PKC. tein kinase C and cGMP/cAMP-dependent kinases. Our results also show that substantial modulation of the T-cell MATERIALS AND METHODS receptor complex and most likely CD3 phosphorylation are not essential for initiating the activation of resting T cells. Instead, T-Cell Preparation. Peripheral blood T lymphocytes from we found a 22- to 24-kDa phosphoprotein whose strong healthy adult volunteers were purified according to Garotta phosphorylation correlated reliably with T-cell activation. and Neri (17) as modified by Emmrich et al. (6). Briefly, mononuclear cells were isolated by Ficoll/metrizoate (Phar- Although B-cell receptors (antibodies) bind antigen indepen- macia) density gradient centrifugation. Monocytes were dently of accessory structures, T-cell receptors (TCR) rec- depleted by adherence to a plastic surface at 37°C for 2 hr. T ifpresented in with self cells were separated from B cells and residual monocytes by ognize antigen only association major rosette formation with (2-aminoethyl)isothiouronium bro- histocompatibility complex (MHC) antigens. T cells bearing mide (hydrobromide, Sigma)-treated sheep erythrocytes fol- the CD4 surface molecule recognize antigen in association lowed by Ficoll/metrizoate gradient centrifugation and lysis with MHC class II structures on the presenting cell, while of erythrocytes in 0.02 M Tris-buffered (pH 7.2) 0.87% CD8-bearing T cells are restricted to antigen recognition in NH4Cl. the context of MHC class I target structures. Coating of Culture Wells with Anti-CD3 and Anti-CD8 To explain this striking dichotomy in MHC restriction, it Monoclonal Antibodies for T-Cell Activation. Flat-bottom 24- was suggested that the CD8 and the CD4 structures them- or 96-well culture plates (Nunc) were first coated with selves, in addition to the TCR, interact with MHC class I and purified goat antimouse IgG [Dianova, Hamburg; 5 ,ug/ml in class II molecules, respectively (1-5). This would imply a isotonic phosphate-buffered saline (PBS)]. The stimulating fixed juxtaposition of TCR-CD3 and CD8 or CD4 on the T antibodies were diluted in 0.5% bovine serum albumin/PBS cell upon antigen presentation. This situation can be mim- at the concentrations indicated for each experiment: anti- icked by presenting to the T cell crosslinked antibodies CD3 at 2-1500 ng/ml (BMA030/IgG2a; a gift of R. Kurrle, against the membrane molecules involved (TCR-CD3 and Behringwerke) and anti-CD8 at 1500 ng/ml (T811/IgGl; a gift CD8 or CD4). of P. Rieber, Munich). When anti-CD3 or anti-CD8 mAbs A pronounced synergism was observed (6-9) between were used alone, the second antibody was replaced by a anti-CD3 and anti-CD4 or between anti-CD3 and anti-CD8 in nonspecific antibody of the same isotype. The stimulating the activation ofthe corresponding T-cell subpopulation. The antibodies were allowed to bind for 4 hr at 37°C. Wells used molecular mechanisms responsible for this synergism have not yet been elucidated. Abbreviations: mAb, monoclonal antibody; SDS, sodium dodecyl Numerous studies, mostly done with T-cell clones or sulfate; TCR, T-cell receptor; MHC, major histocompatibility com- malignant T-cell lines, describe initial events for the activa- plex; IL-2, interleukin 2; IL-2R, IL-2 receptor; IFN-y, interferon y; tion by antigen, by antibodies to the receptor complex, or by PKC, protein kinase C mitogens and/or phorbol esters. These events involve ino- *Present address: Deutsches Krebsforschungszentrum, Im Neuen- sitol phospholipid breakdown, a rapid rise in cytoplasmic free heimer Feld 280, D-6900 Heidelberg 1, F.R.G. tPresent address: Max-Planck-Gesellschaft, Klinische Arbeits- gruppe fur Rheumatologie, Schwabachanlage 10, D-8520 Erlangen, The publication costs of this article were defrayed in part by page charge F.R.G. payment. This article must therefore be hereby marked "advertisement" tPresent address: Ciba-Geigy AG, Pharmaceuticals Research Divi- in accordance with 18 U.S.C. §1734 solely to indicate this fact. sion, R-1056.4.13, CH-4002 Basel, Switzerland. 9689 Downloaded by guest on September 25, 2021 9690 Immunology: Samstag et al. Proc. Natl. Acad. Sci. USA 85 (1988) for culturing unstimulated T cells as controls were coated IL-2 Activity. IL-2 in cell-culture supernatants was mea- with goat anti-mouse IgG and nonspecific IgG2a and IgG1 sured by the ability of the supernatant to promote the mAbs. The plates were rinsed three times with 0.01 M proliferation ([3H]thymidine incorporation) of a cloned T-cell Tris-buffered (pH 7.5) 0.9% NaCl before use. line, CTLL (20). CTLL were grown in serial 1:2 dilutions of Cell Culture for Stimulation of T Cells, 32p Incorporation, test supernatants, and [3H]thymidine incorporation was mea- and Functional Analysis. According to flow cytofluorometric sured over the last 12 hr of a 48-hr culture period. All values analysis, the purified T cells contained no MO1' cells and shown are mean values of triplicate samples and were within were 95-97% CD3-positive. They were suspended at 2.8 x the linear range of the standard curve obtained with human 106 cells per ml in 25 mM Hepes (pH 7.2)-buffered phosphate- recombinant IL-2 (gift of Hoffmann-La Roche). free RPMI 1640 medium containing 2 g of glucose per liter, 2 mM fresh glutamine, 1 mM sodium pyruvate, 50 uM 2- RESULTS mercaptoethanol, penicillin at 100 units/ml, streptomycin at 100 gg/ml, 2% (wt/vol) nondialyzed heat-inactivated human Phosphorylation of a 22- to 24-kDa Protein Not Associated serum, and, ifprotein phosphorylation was to be studied, 25- with CD3 (y, 8, and E Chains) Is Characteristic of T-Cell 30 ,uCi of [32P]orthophosphate (Amersham) per ml (1 Ci = 37 Activation. Our first experiments explored whether TCR- GBq). The T cells were incubated over night in a culture flask CD3 complex phosphorylation and modulation are important humidity to remove signals for activation of resting T cells. In most experiments, at 37TC in 5% C02/95% air and 96% using different donors, CD3 phosphorylation, as revealed by residual monocytes (and to equilibrate intracellular nucleo- SDS/PAGE of CD3 immunoprecipitates followed by auto- side phosphate pools with 32p for phosphorylation experi- radiography, was not detectable. However, total protein ments). For stimulation the cells were then seeded in 0.6-ml phosphorylation in postnuclear cell lysates analyzed by aliquots into the antibody-coated wells and incubated as autoradiography of SDS/PAGE gels showed a striking pre- indicated. Cells were harvested by vigorous pipetting in cold dominant phosphorylation of a 22- to 24-kDa protein (termed PBS. 23 kDa, possibly a double band) in anti-CD3- plus anti-CD8 32P-Labeled Protein Analysis. Approximately 107 labeled (anti-CD3/CD8)-stimulated T cells and less pronounced in cells from six wells were washed two times with 10 ml of only anti-CD3-stimulated T-cells. This 23-kDa protein phos- ice-cold PBS (pH 7.2) and once with 3 ml ofPBS (pH 8.0) and phorylation after 25 and 42 hr of stimulation is shown in Fig. lysed for 30 min at 4°C in 170 ,ul of 1% Nonidet P-40 (Sigma) 1. The preferential phosphorylation ofthe 23-kDa protein was in PBS (pH 8.0) containing leupeptin at 1 mg/ml, soybean quantified by determining the ratio of the 23-kDa protein to trypsin inhibitor at 20 ,g/ml, aproteinin at 10 Ag/ml, and 5 a 38-kDa protein phosphorylation from laser scans of the mM 4-nitrophenyl phosphate (all from Sigma).
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • T Cells the Usual Subsets
    T cells: the usual subsets Chen Dong and Gustavo J. Martinez T cells have important roles in immune responses and function by directly secreting soluble mediators or important for adaptation of immune responses in different microenvironments and might be particularly through cell contact-dependent mechanisms. Many T cell subsets have been characterized. Although relevant for host defence against pathogens that colonize different tissues. Distinct T cell subsets, or effector T cells were originally considered to be terminally differentiated, a growing body of evidence has differentiation states, can be identified based on the cell surface markers expressed and/or the effector challenged this view and suggested that the phenotype of effector T cells is not completely fixed but is molecules produced by a particular T cell population. This Poster summarizes our current understanding of more flexible or plastic. T cells can have ‘mixed’ phenotypes (that is, have characteristics usually the surface markers, transcriptional regulators, effector molecules and functions of the different T cell associated with more than one T cell subset) and can interconvert from one subset phenotype to another, subsets that participate in immune responses. Further knowledge of how these T cell subsets are regulated IMMUNOLOGY although instructive signalling can lead to long-term fixation of cytokine memory. T cell plasticity can be and cooperate with each other will provide us with better tools to treat immune-related diseases. Cytotoxic T cell Exhausted T cell
    [Show full text]
  • T Lymphocytes + and CD8 +CD4 TCR/CD3 Complex in Immortalized Mature -Deficient Γ Signaling Through A
    Signaling Through a CD3γ-Deficient TCR/CD3 Complex in Immortalized Mature CD4+ and CD8+ T Lymphocytes This information is current as Alberto Pacheco-Castro, David Alvarez-Zapata, Pilar of September 25, 2021. Serrano-Torres and José R. Regueiro J Immunol 1998; 161:3152-3160; ; http://www.jimmunol.org/content/161/6/3152 Downloaded from References This article cites 47 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/161/6/3152.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Signaling Through a CD3g-Deficient TCR/CD3 Complex in Immortalized Mature CD41 and CD81 T Lymphocytes1 Alberto Pacheco-Castro,2 David Alvarez-Zapata,2 Pilar Serrano-Torres, and Jose´R. Regueiro3 The biologic role of each CD3 chain and their relative contribution to the signals transduced through the TCR/CD3 complex and to downstream activation events are still controversial: they may be specialized or redundant.
    [Show full text]
  • 18F-Farag PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
    Journal of Nuclear Medicine, published on November 6, 2020 as doi:10.2967/jnumed.120.249078 18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy Jelena Levi1*, Samuel Goth1, Lyna Huynh1, Tina Lam1, Tony L Huynh2, Brailee Schulte2, Juliet A Packiasamy1 1CellSight Technologies Incorporated, San Francisco, California; 2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; *Corresponding Author Jelena Levi, PhD 185 Berry street, San Francisco, 94107, CA Email: [email protected] Running Title: [18F]F-AraG for CD8 profiling of tumors Financial statement: This work was supported by National Institutes of Health Grants NCI SBIR HHSN261201800024C (JL). Conflict of Interest Statement: JL, SG, LH, TL and JP are or were employed by CellSight Technologies. CellSight Technologies Incorporated is commercializing [18F]F-AraG as a PET tracer for evaluation of immune response in immunotherapy. No other potential conflicts of interest relevant to this article exist. ABSTRACT Majority of the clinical trials exploring various combinations of chemo- and immunotherapy rely on serial biopsy to provide information on immune response. The aim of this study was to assess the value of 18F-FAraG as a non-invasive tool that could profile tumors based on the key players in adaptive antitumor response, CD8+ cells, and evaluate immunomodulatory effects of chemotherapy. Methods. To evaluate the ability of 18F-FAraG to report on the presence of CD8+ cells within the TME, we imaged a panel of syngeneic tumor models (MC38, CT26, LLC, A9F1, 4T1 and B16F10), and correlated the signal intensity with the number of lymphocytes found in the tumors.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Identification of 18 Immune Cell Subsets Using 13-Color Panel
    Immunophenotyping Identification of 18 immune cell subsets in human blood using a 13-color panel Background Cell type Function Phenotype Flow cytometry has become the method of choice for Eosinophils Parasitic immunity CD45+, SSCmid/hi, CD14 –, CD16 –, CD19– immunophenotyping and identifying specific cellular + mid/hi subsets. Within seconds, it provides a thorough overview of Neutrophils Innate Immunity CD45 , SSC , CD14 –, CD16+, CD19– the major cell types that constitute a sample. Using multiple + mid markers simultaneously increases the number of parameters Classical Phagocytosis of CD45 , SSC , monocytes pathogens and CD14+, CD16– that can be analyzed per run and decreases the amount of antigen presentation starting material required to perform an assay. This can be Intermediate Phagocytosis of CD45+, SSCmid, critical for precious sample material and long-term immune- monocytes pathogens and CD14+, CD16mid monitoring studies. In this application note, we demonstrate antigen presentation 13-color immunophenotyping of human peripheral blood Non-classical Phagocytosis of CD45+, SSCmid, + + mononuclear cells (PBMCs) using the MACSQuant® Analyzer 16, monocytes pathogens and CD14 , CD16 antigen presentation a compact and reliable benchtop flow cytometer equipped + low + with three lasers. The markers selected allow for the Class-switched Adaptive immunity CD45 , SSC , CD19 , memory B cells CD27+, IgD–, CD14– simultaneous identification and analysis of 18 different cell Non-switched Adaptive immunity CD45+, SSClow, CD19+, populations, thus maximizing the amount of information that memory B cells CD27+, IgD+, CD14– can be retrieved from the sample material analyzed. This is Naive B cells Adaptive immunity – CD45+, SSClow, CD19+, critical when input material is limited, as is often the case for non-antigen CD27–, IgD+, CD14– pediatric or disease studies.
    [Show full text]
  • Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries with Limited Resources and for Triaging Cases Before
    AJCP /ORIGINAL ARTICLE Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers Downloaded from https://academic.oup.com/ajcp/article-abstract/145/5/687/2195691 by World Health Organization user on 09 January 2019 Maria Giulia Disanto, MD,1 Maria Raffaella Ambrosio, MD, PhD,2 Bruno Jim Rocca, MD, PhD,2 Hazem A. H. Ibrahim, FRCPath, PhD,1,3 Lorenzo Leoncini, MD, PhD,2 and Kikkeri N. Naresh, MD, FRCPath1 From the 1Department of Histopathology, Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom; 2Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy; and 3Department of Histopathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Key Words: Lymphoma; B-cell lymphoma; Immunohistochemistry; Diagnosis; Classification; Developing countries Am J Clin Pathol May 2016;145:687-695 DOI: 10.1093/AJCP/AQW060 ABSTRACT Lymphomas are a collection of different malignancies “arising” from lymphoid cells. They include about 49 entities, Objectives: Establish and validate optimal minimal and over 19 provisional entities and subsets.1 About 85% of immunohistochemistry panels for usage in a staged lymphomas are of B-cell origin. Precision in lymphoma diag- algorithmic manner for precise diagnosis of B-cell nosis requires expertise and infrastructure. The entities are lymphomas in countries with limited resources. Suggest defined based on morphology, immunohistochemistry (on short panels of immunostains to be used in referring units some occasions in situ hybridization), cytogenetics/fluores- that refer suspected lymphomas to specialist diagnostic cent in situ hybridization (FISH), molecular genetics and clin- centers in resourceful countries.
    [Show full text]
  • Cd4/Cd8 Panel, Blood
    Lab Dept: Flow and Immunology Test Name: CD4/CD8 PANEL, BLOOD General Information Lab Order Codes: C48P Synonyms: Helper/Suppressor Ratio; T- cells; T-cell subsets; T-cell phenotyping See also: Immune Status Panel and Comprehensive Immune Status Panel CPT Codes: 86359 – T cells, total count 86360 – T cells; absolute CD4 and CD8 count, including ratio Test Includes: CD4(CD3+) and CD8(CD3+) relative percentages, absolute values and a calculated Helper/Suppressor ratio. Logistics Test Indications: This is a minimal antibody panel to monitor immune status. Lab Testing Sections: Flow Cytometry Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: 3 times weekly determined by volume. Transport collected specimen immediately to Flow Cytometry. Routine testing is not available on weekends or holidays. Therefore, specimens cannot be used if drawn the day before a 3 day weekend such as Memorial Day, Labor Day or major holiday that falls on a Monday or Friday. Turnaround Time: 1 – 3 days Special Instructions: See Test Availability Specimen Specimen Type: Whole blood Container: Lavender top (EDTA) tube Draw Volume: 2 mL blood in a 2 mL Lavender (EDTA) tube Minimum volume: 0.5 mL in an EDTA microtainer Collection: Routine venipuncture Special Processing: Keep sample at room temperature and forward promptly to the laboratory. Do not centrifuge, refrigerate, or freeze sample. Patient Preparation: None Sample Rejection: Specimens will not be processed that are clotted; hemolyzed; greater than 72 hours old; collected in the wrong tube type (0.5 mL in a 2 mL tube), or that have been held or handled at a temperature other than room temperature Interpretive Reference Range: Age-dependant reference ranges provided with results.
    [Show full text]
  • Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367
    Medicare Local Coverage Determination Policy Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367 CMS Policy for Alaska, Arizona, Idaho, Montana, North Dakota, Medically Supportive Oregon, South Dakota, Utah, Washington, and Wyoming ICD Codes are listed Local policies are determined by the performing test location. This is determined by the state on subsequent page(s) in which your performing laboratory resides and where your testing is commonly performed. of this document. Coverage Indications, Limitations, and/or Medical Necessity Flow cytometry (FCM) is a complex process to examine blood, body fluids, CSF, bone marrow, lymph node, tonsil, spleen and other solid tissues. The use of peripheral blood and fine needle aspirate material avoids more invasive procedures for diagnosis. A flow cytometer evaluates the physical and/or chemical characteristics of single cells as the cells pass individually in a fluid stream through a measuring device. Surface receptors, intracellular molecules, and DNA bind with fluorescent dyes that allow detection and evaluation. When light of one wave length excites electrons of certain chemicals to energy levels above their ground state and upon return to ground state emits light of a longer wavelength, fluorescence is produced. A flow cytometer detects cell characteristics by measuring the fluorescence produced by fluorochromes conjugated either directly with cell components or conjugated to antibodies directed against cell components. Indications • Cytopenias and Hypercellular Hematolymphoid Disorders Hematolymphoid neoplasia can present with cytopenias (anemia, leucopenia and/or thrombocytopenia) or elevated leukocyte counts. If medical review and preliminary laboratory testing fails to reveal a cause, bone marrow aspiration and biopsy are indicated to rule out an infiltrative process or a stem cell disorder.
    [Show full text]
  • MGD011, a CD19 X CD3 Dual-Affinity Retargeting Bi-Specific Molecule Incorporating Extended Circulating Half-Life for the Treatment of B-Cell Malignancies
    Published OnlineFirst September 23, 2016; DOI: 10.1158/1078-0432.CCR-16-0666 Cancer Therapy: Preclinical Clinical Cancer Research MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies Liqin Liu, Chia-Ying K. Lam, Vatana Long, Lusiana Widjaja, Yinhua Yang, Hua Li, Linda Jin, Steve Burke, Sergey Gorlatov, Jennifer Brown, Ralph Alderson, Margaret D. Lewis, Jeffrey L. Nordstrom, Scott Koenig, Paul A. Moore, Syd Johnson, and Ezio Bonvini Abstract Purpose: CD19, a B-cell lineage-specific marker, is highly autologous B-cell depletion in PBMCs from both species. represented in B-cell malignancies and an attractive target for MGD011-mediated killing was accompanied by target-depen- therapeutic interventions. MGD011 is a CD19 x CD3 DART dent T-cell activation and expansion, cytokine release and bispecific protein designed to redirect T lymphocytes to eliminate upregulation of perforin and granzyme B. MGD011 demon- CD19-expressing cells. MGD011 has been engineered with a strated antitumor activity against localized and disseminated modified human Fc domain for improved pharmacokinetic (PK) lymphoma xenografts reconstituted with human PBMCs. In properties and designed to cross-react with the corresponding cynomolgus monkeys, MGD011 displayed a terminal half-life antigens in cynomolgus monkeys. Here, we report on the preclin- of 6.7 days; once weekly intravenous infusion of MGD011 at ical activity, safety and PK properties of MGD011. dosesupto100mg/kg, the highest dose tested, was well Experimental Design: The activity of MGD011 was evaluated tolerated and resulted in dose-dependent, durable decreases in several in vitro and in vivo models.
    [Show full text]
  • CD3+CD5+CD4-CD8-) Alpha/Beta T Cell Receptor-Bearing Cells
    Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells. This information is current as of October 2, 2021. M Bruley-Rosset, I Miconnet, C Canon and O Halle-Pannenko J Immunol 1990; 145:4046-4052; ; http://www.jimmunol.org/content/145/12/4046 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription by guest on October 2, 2021 Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1990 by American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. 0022-1767/90/14512-4046$02.00/0 THEJOURNAL OF IMMUNOLCGY Vol. 145.4046-4052. No. 12. December 15. 1990 Copyright 0 1990 by The American Association of lmmunologists Printed In U.S.A. Mls" GENERATED SUPPRESSORCELLS I. Suppression is Mediated by Double-Negative (CD3+CDVCD4-CD8-) a/@ T Cell Receptor-Bearing Cells' Grafting of cells from B10.D2 (H-2d)donors into H- The GVHR3 remains a major problem after bone mar- 2 compatible lethally irradiated (DBA/2 x B1O.DZ)Fl row transplantation, even in MHC-compatible donor-re- hostsresults in a severe graft-vs-host reaction cipient combinations.
    [Show full text]
  • Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature
    cells Article Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature 1, 2, 1, 1, Sónia Fonseca y, Vanessa Pereira y, Catarina Lau z, Maria dos Anjos Teixeira z, Marika Bini-Antunes 3 and Margarida Lima 1,* 1 Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001 Porto Porto, Portugal; [email protected] (S.F.); [email protected] (C.L.); [email protected] (M.d.A.T.) 2 Department of Clinical Pathology, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), 4434-502 Vila Nova de Gaia, Portugal; [email protected] 3 Laboratory of Immunohematology and Blood Donors Unit, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001Porto, Portugal; [email protected] * Correspondence: [email protected]; Tel.: + 351-22-20-77-500 These authors contributed equally to this work. y These authors contributed equally to this work. z Received: 10 February 2020; Accepted: 13 March 2020; Published: 16 March 2020 Abstract: Gamma delta T cells (Tc) are divided according to the type of Vδ and Vγ chains they express, with two major γδ Tc subsets being recognized in humans: Vδ2Vγ9 and Vδ1.
    [Show full text]